Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models 1st ed. 2020 Edition

  • NH00017072
21 $
 

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models 1st ed. 2020 Edition

 
 This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine.  Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.
 

Product details

  • Publisher : Springer; 1st ed. 2020 edition (October 1, 2020)
  • Language : English
  • Hardcover : 241 pages